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ABSTRACT Cytotoxic T lymphocytes (CTLs) are thought
to play a crucial role in the termination of the acute primary
HIV-1 syndrome, but clear evidence for this presumption has
been lacking. Here we demonstrate positive selection of HIV-1
proviral sequences encoding variants within a CTL epitope in
Nef, a gene product critical for viral pathogenicity, during and
after seroconversion. These positively selected HIV-1 variants
carried epitope sequence changes that either diminished or
escaped CTL recognition. Other proviruses had mutations
that abolished the Nef epitope altogether. These results pro-
vide clear evidence that CTLs exert selection pressure on the
viral population in acute HIV-1 infection.
Infection with HIV-1 is often heralded by a clinical illness
characterized by rash, fever, and lymphadenopathy. Simulta-
neously, HIV-1 RNA is detectable in the plasma at concen-
trations as high as 22 3 106 copies per ml (1). In most patients
studied, the viremia diminishes by 10- to 200-fold within a few
weeks (1–3). This suppression, which is as effective as that
achieved by single anti-retroviral drugs (4, 5), has been attrib-
uted to the immune response and is thought to be mediated by
cytotoxic T lymphocytes (CTLs). Although CTLs directed
against HIV first become detectable as the viremia declines (6,
7), there has been no direct evidence that this cellular immune
response can modulate the natural history of HIV-1 infection.
Some authors have doubted whether CTLs play any role in
controlling persistent viral infections (8, 9). Here, by detailed
genetic analysis, we show that CTLs exert a significant selec-
tion force on the virus population during primary HIV-1
infection and cause the rapid emergence of escape variants.
MATERIALS AND METHODS
Blood Donor. Donor SC2 is a 36-year-old homosexual male
with a history of regular unprotected sexual intercourse with
men known to be HIV-seropositive. A previous HIV antibody
test (Jan. 10, 1995) had been negative. In October 1995, he was
admitted to hospital with a sore throat, fever, headache, and
photophobia; symptoms persisted until mid-November. Blood
sampled on Oct. 13, 1995 tested HIV p24 antigen-positive
(.100 pgyml), antibody-negative (determined by standard
ELISA methods; Abbott); a second sample 6 days later tested
HIV p24 antigen-positive (.500 pgyml), HIV gp41 antibody-
positive, and HIV p31 antibody-, p24 antibody-, p17 antibody-,
and gp36 antibody-negative. Together these results imply that
donor SC2 acquired HIV-1 in September or early October
1995.
HLA Class 1 Determination. HLA class I typing was per-
formed using sequence-specific PCRs as described previously
(10, 11).
Viral Load Measurement. Plasma HIV-1 RNA was quan-
tified using a commercially available reverse transcriptase-
PCR technique (Amplicor; Roche Diagnostics).
Generation of Bulk Cultured Lymphocytes. Heparinized
blood samples (40–60 ml) were separated by Ficoll–Hypaque
density gradient centrifugation, and the peripheral blood
mononuclear cells (PBMCs) were washed and resuspended in
RPMI-1640 medium (GIBCO) with 10% fetal calf serum
(R10). Bulk cultures were prepared by the addition of autol-
ogous phytohemagglutinin-activated lymphocytes to the PB-
MCs as previously described (12).
Generation of CTL Lines. CTL lines were derived from
donor PBMCs or bulk cultures as previously described (12).
Cytotoxicity Assays. Target cells in cytotoxicity assays were
autologous or HLA-matched Epstein–Barr virus-transformed
B cells prepulsed with 10 mM peptide or infected with recom-
binant vaccinia virus (rVV) and labeled with 51Cr (Amer-
sham). Peptides were synthesized using standard fluorenylme-
thoxycarbonyl (Fmoc) techniques and were .90% pure as
determined by HPLC (Research Genetics, Huntsville, AL and
Multiple Sclerosis Society Peptide Laboratory, Oxford, U.K.).
Vaccinia infections were effected at 3–5 plaque-forming units
per cell (1 h) followed by 16 h of incubation before 51Cr
labeling. The construction of rVV expressing p17Gag has been
described previously (13); rVV expressing influenza nucleo-
protein was used to infect control target cells. Targets were
plated out at 5 3 103 cells per well in round-bottomed
microtiter plates (Nunclon, Naperville, IL) and incubated at
378C with either R10, effector cells at the effector:target (E:T)
ratios shown (see Fig. 1) or 5% Triton X-100 in a total volume
of 150 ml. All assays were performed in duplicate. Supernatant
was assayed at 4–6 h, and specific lysis was calculated as 1003
(experimental lysis 2 spontaneous lysis)y(maximum lysis 2
spontaneous lysis). Spontaneous release was ,30% of deter-
gent release for all assays shown.
Functional HLA Binding Assays. Target cells were pulsed
with 10 mM peptide for 1 h at 1.5, 5, 10, 16, and 24 h before
the assay, then washed twice and incubated in R10 until
labeling with 51Cr 1.5 h before cytotoxicity assay.
PCRs, Product Cloning, and Sequencing. Genomic DNA
was extracted directly from fresh uncultured PBMCs used to
set up the bulk cultures (Puregene, Gentra Systems). Proviral
nef and p17 gag were amplified using nested PCRs. Primers for
the nef PCR were: 59-GTAGCTGAGGGGACAGATAG-39y
59-TGCTAGAGATTTTCCACAC-39 for the primary reac-
tion, and 59-GAAGAATAAGACAGGGCT-39y59-AGGCT-
CAGATCTGGTCTAAC-39 for the secondary reaction. The
primary reaction mix contained 1 mg of DNA, 2.5 units of Taq
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polymerase, 10 ml of 103 KCl buffer containing 0.015 M
MgCl2 (Bioline, London), 0.2 mM each dNTP, and 0.5 mM
each primer in a total volume of 100 ml. Cycling parameters
were 5 min at 948C, 1 min at 528C, and 1 min at 728C, followed
by 1 min at 948C, 1 min at 528C, and 1 min at 728C for 30 cycles.
The secondary reaction used 1 ml of primary product; condi-
tions were as for the primary except that the annealing
temperature was 508C. Primers for the p17 gag PCR were:
5 9 -ACTAGCGGAGGCTAG-3 9y5 9 -GTTCTAGGT-
GATATGG-39 for the primary reaction, and 59-CAGTTCTA-
GATCTAGTAATTTTGGCTGACC-39y59-GCTAGAAT-
TCCATGGGTGCGAGAGCGT-39 for the secondary reac-
tion. The primary reaction mix contained 1 mg of DNA in
buffer containing 2.5 units of Taq polymerase, 0.05 M KCl,
0.01 M Tris (pH 8), 0.003 M MgCl2, 0.2 mM each dNTP, and
1 mM each primer. Cycling parameters were 5 min at 948C, 1
min at 488C, and 1 min at 728C, followed by 1 min at 948C, 1
min at 488C, and 1 min at 728C for 35 cycles. The secondary
reaction used 1 ml of primary product; conditions were as for
the primary except that the annealing temperature was 678C.
PCR products were cloned into the T-vector system (Amer-
sham), and epitopes were sequenced with insert-specific prim-
ers (59-GCCTGGCTAGAAGCA-39 for HLA B8 nef and
59-TGATGTACACAATAGAG-39 for HLA B8 p17-3 gag)
using the United States Biochemical Sequenase version 2.0
protocol.
RESULTS
The tissue type of donor SC2 was determined as HLA A1,
B7yB8, Cw0701yCw0702, DR4yDR16. Serial CD41 lympho-
cyte counts and viral load measurements are shown in Table
1. Synthetic peptides representing known HIV-1 CTL epitopes
restricted by these HLA molecules were pulsed on to B
lymphoblastoid cell lines, and the pulsed cells were then used
to screen bulk cultured lymphocytes for HIV-1-specific CTL
activity at each of four time points. A strong response to aHLA
B8-restricted epitope in Nef (FLKEKGGL; Nov. 3, 1995) and
a weaker response to a HLA B8-restricted epitope in p17 Gag
(GGKKKYKL, p17-3; Oct. 19, 1995) were detected (Fig. 1). A
response to the Nef epitope was subsequently detectable in
CTL lines grown from later time points (data not shown).
Uncultured peripheral blood leukocyte proviral DNA from
four time points was amplified, cloned, and analyzed for
sequence variation within and near the regions encoding the
two targeted epitopes (Fig. 2).
Serial analysis of nef sequences demonstrated amino acid
sequence variation confined chief ly to the epitope
FLKEKGGL, suggesting positive selection for viruses bearing
variants within this region of the gene (Fig. 3a). In contrast, the
sequence of this nef region was invariant at amino acid level in
a total of 27 clones from two time points from a HLA
B8-negative donor with primary infection and in a total of 51
clones from two time points from a HLA B8-negative donor
soon after seroconversion (data not shown).
To assess selection intensity, we examined the ratio of the
rate of nonsynonymous to synonymous nucleotide mutations
(dNydS), where a ratio .1 indicates positive selection (16).
With this approach, we found that dN exceeded dS in the
region encoding the B8 Nef epitope on Jan. 30, 1996 and April
2, 1996, while an anti-Nef CTL response was still detectable on
June 25, 1996 (Fig. 3b). The value of dNydS for the whole
amplified fragments did not exceed 0.84. Elsewhere in the
amplified sequence, dN exceeded dS only at the 39 end on Jan.
30, 1996; this region corresponds to a HLA B7-restricted
FIG. 1. Recognition of CTL epitopes by donor SC2 bulk cultured lymphocytes. (a) HLA B8 Nef (FLKEKGGL) response (Nov. 3, 1995). (b
and c) HLAB8 p17-3 Gag (GGKKKYKL) response (Oct. 19, 1995). Screening peptides used were: GGKKKYKL (p17-3 Gag; ref. 13), GEIYKRWII
(p24-13 Gag; ref. 13), DCKTILKAL (p24-20 Gag; ref. 13), GPKVKQWPL (Pol; ref. 14), and FLKEKGGL (Nef; P.J.R.G., unpublished work).
Table 1. Serial CD41 lymphocyte counts and plasma HIV-1 RNA
loads from donor SC2
Sample date
CD41, 3 106
per liter
Viral load,
copies per ml
Oct. 19, 1995 384 7,600,000
Nov. 3, 1995 518 ND
Jan. 30, 1996 ND 715,000
April 2, 1996 330 700,000
ND, not done.
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epitope (amino acids 102–112; P.J.R.G., unpublished obser-
vation).
Two sequences were found in the p17-3 gag epitope (Fig. 2b).
Both were variant compared with the consensus index se-
quence (GGKKKYKL; ref. 17).
CTL lines specific for the index HLA B8 Nef epitope
(FLKEKGGL) were derived from donor SC2 (Nov. 3, 1995
blood sample) and used to test the effects of the detected
epitope variation on CTL recognition. Some variants (N5, E5,
Q5, and D4) were poorly recognized, while others (I2yN5,
E3yN5, and G4yN5) escaped recognition completely (Fig. 4a).
The majority of variants encoded mutations at the HLA B8
anchor position 5 (Fig. 2a), and these changes resulted in
reduced binding efficiency (Fig. 4b). Similarly, a HLA-B8
p17-3 Gag index-specific CTL line from donor SC2 showed
diminished recognition of the p17-3 Q5 variant (Fig. 4c).
In addition to variants within the HLA B8 Nef epitope, a
number of proviral clones contained mutations that abolished
this epitope altogether (Fig. 5).
DISCUSSION
Naturally occurring mutations in HIV-1 CTL epitopes have
been described that reduce or abolish CTL recognition (13,
18). However, the role of CTLs in controlling the growth of
HIV-1 in the host remains controversial, in part because there
is no definitive evidence that CTL activity has a direct effect
on the viral genotype. During primary infection, there is a
temporal correlation between the development of anti-HIV-1
CTL responses and the decline of initial viremia (6, 7). We
reasoned that if CTLs are important in limiting viral replica-
tion, then evidence of this effect should be apparent during
such a period of intense CTL activity on a large viral popu-
lation. Here we demonstrate positive selection for CTL escape
mutations in a HIV-1 Nef epitope in a recent seroconverter;
this selection was confined to the epitope and occurred in the
presence of a strong CTL response directed against it. These
results support the contention that CTLs play an important
role in controlling viral growth in the host.
When the anti-Nef CTL response was first detected (Nov. 3,
1995), a deletion and two novel epitope sequences were
present in nef in the proviral sequences. Subsequently, as the
viral load fell, the array of escape variants expanded. Several
months after the seroconversion illness, anti-Nef CTLs were
detectable, while few HIV-1 clones in peripheral blood con-
tained the Nef epitope sequence originally detected in this
patient. Analysis of the genetic variation responsible for these
epitope changes revealed that nucleotide substitutions pro-
ductive of amino acid change exceeded silent substitutions
within the epitope region, providing strong evidence of posi-
tive selection at this site in Nef (Fig. 3b). We cannot formally
exclude the possibility that the observed nucleotide substitu-
tions were selected by forces other than the immune response,
such as structural constraints at the RNA or protein level (19).
However, the confinement of the nonsynonymous substitu-
tions and the high dNydS ratio to the epitope encoding region,
the absence of such substitutions in the control subjects, and
the demonstration that the variant peptides failed to be
recognized by the patient’s own CTLs indicate that CTL-
mediated selection is the more likely selection force. In
addition, variants that failed to escape CTL recognition (S1,
L1) were poorly represented in the provirus population (Figs.
2a and 4a).
Further evidence of CTL-mediated positive selection in this
individual came from the observation of deletions in the region
of nef encoding the HLA B8-restricted epitope (Fig. 5). This
observation is reminiscent of the epitope deletions detected
following the infusion of an expanded CTL clone that recog-
nized a single HLA A3 Nef epitope into a HIV-1-infected
individual (20).
At the time of the first blood sample (Oct. 19, 1995), only
variant virus sequences were detectable in the p17-3 Gag
FIG. 2. Proviral sequence variation in HIV-1 epitopes from SC2.
(a) HLA B8 Nef. (b) HLA B8 p17-3 Gag. Variant residues are
highlighted.
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FIG. 3. Nucleotide and amino acid sequence variation in the region of Nef containing the HLA B8 epitope. For donor SC2, a number of clones
from each time point (19 from each of the first three time points, 18 from the fourth time point) were sequenced further to incorporate regions
flanking the epitope (nucleotides 114–395, amino acids 38–132, numbered according to the nef reference sequence HIV-LAI). (a) The Kabat–Wu
index (KWI), calculated at each amino acid position as the number of different residuesyfrequency of the commonest residue, provides a measure
of variability; an index of 1 indicates that no variation was detected at the relevant position (15). The HLA B8 epitope (amino acids 90–97) is shaded.
(b) The rates of nonsynonymous (dN) and synonymous (dS) nucleotide substitutions were calculated in a sliding window of 60 nt over all pairwise
comparisons between clones at a given time point, according to the method of Nei and Gojobori (16). The window is advanced in steps of three
nucleotides, and the values of dN and dS are plotted against the central nucleotide in the window. dN rises sharply at the border of the region
encoding the HLA B8 epitope, and exceeds dS over this region. The apparent extension of positive selection beyond the limits of the epitope reflects
window width, not flanking mutations. Dotted line, synonymous substitutions; solid line, nonsynonymous substitutions.
FIG. 4. (a) Altered recognition of variant Nef epitopes by donor SC2 CTLs. 51Cr-labeled HLAB8-matched targets were added directly to 96-well
plates containing peptide, and therefore peptide was present at the concentrations drawn for the duration of the assay. Targets and peptide were
incubated at room temperature for 15 min before the addition of effector cells. (b) Functional HLA binding assay. Target cells pulsed with variant
peptides containing mutations at position 5 (a HLA B8 anchor position) were not recognized by donor SC2 CTLs after 6 h (N5 and E5) and 10 h
(Q5), suggesting that these peptides bind poorly and have high off-rates. (c) The p17-3 Gag Q5 variant is poorly recognized by donor SC2-derived
GGKKKYKL-specific CTLs.
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epitope (Fig. 2b). This suggests that the anti-p17-3 Gag CTL
response, elicited earlier by the prototype sequence, had
already driven out escape variants to fixation; however, since
we did not detect index sequence in DNA proviruses, infection
with virus bearing the p17-3 Q5 variant and stimulation of a
crossreactive response cannot be excluded.
Using dNydS in a comparison between HIV isolates, Seibert
et al. (21) found evidence of positive selection in Env but not
in Gag and concluded that anti-Gag CTL do not exert signif-
icant selection on the virus. It is presumed that positive
selection on Env is antibody-mediated, as in the case of
influenza A virus surface glycoproteins (gp; ref. 22). However,
calculation of dN and dS in a sliding window can be used to
delimit precise regions within a gene that are subject to locally
focused selection (23). This technique can reveal significant
positive selection in gene segments, even if the value of dNydS
averaged over the whole gene does not suggest that selection
is occurring—for example, in the regions of major histocom-
patibility complex class I genes that encode the antigen
recognition site (24).
In a systematic study of database sequences, Endo et al. (23)
estimated that dN exceeded dS over the whole gene in 17y3595
(0.5%) groups of related genes. Of these 17 gene groups, 9
were the surface proteins of parasites or viruses, which are
exposed to antibody-mediated selection. These results empha-
size that positive selection operating over the full length of a
gene is an uncommon event in evolution, particularly where
the gene encodes an intracellular protein. However, positive
selection has been demonstrated over the full length of the Tax
(transactivator) protein of the human T cell leukemia virus
type 1 (HTLV-1); this protein is the dominant target antigen
of the intense anti-HTLV-1 CTL response (25). The Tax
protein, like the Nef protein of HIV-1, is not expressed in an
intact form on the surface of infected cells and is therefore
removed from the pressure of antibody-mediated selection. It
is likely that the positive selection in this case is exerted by the
anti-Tax CTL response; however, CTLs in HTLV-1 infected
individuals frequently recognize several epitopes in Tax (26),
and therefore the high dNydS ratio is less clearly localized to
a given CTL epitope.
Selection of CTL escape variants in vivo was first demon-
strated by Pircher et al. (27) in lymphocytic choriomeningitis
virus (LCMV) infection. In this study, the diversity of the CTL
response was experimentally limited by using mice transgenic
for a T cell receptor specific for the LCMV gp antigen, thereby
producing conditions in which the CTLs exerted intense
selection pressure on the gp epitope in isolation. The restricted
T cell diversity that has been observed during the primary CTL
response to HIV-1 may facilitate escape in a similar way to the
LCMV model (28).
Sequencing of HIV-1 in donors with primary infection has
demonstrated substantial homogeneity, particularly in the
gp120 region of env; however, some rapid sequence diversifi-
cation has also been observed, especially within p17 gag and nef
(29–31). Previous studies correlating the decline of initial
viremia with dominant CTL responses have failed to identify
escape variants within a targeted epitope in gp41 (32). How-
ever, a recent study found escape sequences in a gp160 epitope
7 weeks after infection in a patient with a monospecific
immunodominant response (33).
In this study, we have demonstrated positive selection of
CTL escape variants within Nef during primary HIV-1 infec-
tion. Although the phenotypic effects of these immune-
selected Nef variants remain untested, viruses carrying nef
gene defects have been associated with attenuated pathoge-
nicity (34).
We conclude that HIV-1 variants that escape CTL recog-
nition have a selective advantage during the early phase of
infection. These mutant viruses may represent forms which
help propagate the viremia that persists after seroconversion.
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